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Abstract
Background: Portacaval shunting in rats produces a reduction of hepatic oxidant scavenging
ability. Since this imbalance in hepatic oxidant/antioxidant homeostasis could coexist with systemic
changes of oxidant stress/antioxidant status, plasma oxidants and antioxidant redox status in
plasma of portacaval shunted-rats were determined.
Results: Male Wistar male: Control (n = 11) and with portacaval shunt (PCS; n = 11) were used.
Plasma levels of the oxidant serum advanced oxidation protein products (AOPP), lipid
hydroperoxides (LOOH), the antioxidant total thiol (GSH) and total antioxidant status (TAX)
were measured. Albumin, ammonia, Aspartate-aminotransferase (AST), Alanine-aminotransferase
(ALT), thiostatin and alpha-1-acid glycoprotein (α1-AGP) were also assayed 4 weeks after the
operation. AOPPs were significantly higher (50.51 ± 17.87 vs. 36.25 ± 7.21 μM; p = 0.02) and TAX
was significantly lower (0.65 ± 0.03 vs. 0.73 ± 0.06 mM; p = 0.007) in PCS compared to control rats.
Also, there was hypoalbuminemia (2.54 ± 0.08 vs. 2.89 ± 0.18 g/dl; p = 0.0001) and
hyperammonemia (274.00 ± 92.25 vs. 104.00 ± 48.05 μM; p = 0.0001) and an increase of thiostatin
(0.23 ± 0.04 vs. 0.09 ± 0.01 mg/ml; p = 0.001) in rats with a portacaval shunt. The serum
concentration of ammonia is correlated with albumin levels (r = 0.624; p = 0.04) and TAX
correlates with liver weight (r = 0.729; p = 0.017) and albumin levels (r = 0.79; p = 0.007)
Conclusion: These findings suggest that in rats with a portacaval shunt a systemic reduction of
oxidant scavenging ability, correlated with hyperammonemia, is principally produced. It could be
hypothesized, therefore, that the reduced antioxidant defences would mediate a systemic
inflammation.
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Portosystemic collateral circulation is a frequent compli-
cation of chronic liver disease [1,2]. The portacaval
shunted rat is an experimental model of great interest for
studying the metabolic alterations related to a portosys-
temic shunt [3]. Particularly, in this model it has been
described that, portal blood flow deprivation (long-term
ischemia) may make the atrophic liver more susceptible
to oxidant-induced injury because the oxidant scavenging
system of the liver decreases [4].
However, recent evidence has shown that the altered
redox status in liver disease is not confined to the diseased
liver, but that it is a systemic phenomenon involving ext-
rahepatic tissues [5]. So, the determination of oxidant and
antioxidant plasma levels in portacaval shunted rats could
broaden the knowledge of the systemic pathophysiologi-
cal mechanisms, which are activated by the systemic
bypass of the portal blood flow.
This study has been carried out to determine serum
advanced oxidation protein products (AOPP), lipid
hydroperoxides (LOOH), total serum antioxidants (TAX),
total thiols and albumin as markers of the plasma redox
status.
Results
Body and liver weights
Rats with portacaval shunt (PCS) show a body weight
(BW) decrease (p < 0.001) during the 4 weeks of postop-
erative evolution. Liver weight (LW) and LW/FBW ratio
are also inferior (p < 0.001) in rats with PCS in relation-
ship to control rats (Table 1).
Hepatic liver function assays
Aspartate-aminotransferase (AST) (p = 0.004), alanine-
aminotransferase (ALT) (p = 0.0001), ammonia (p =
0.0001) and thiostatin (p = 0.0001) serum levels are
higher in PCS-rats compared to control rats. On the con-
trary, albumin (p = 0.0001) and α1-acid glycoprotein (α1-
AGP) (p = 0.04) are lower in PCS-rats (Table 2).
Redox status
The serum advanced oxidation protein product (AOPP)
level increases (p = 0.02) whereas total antioxidant status
(TAX) decreases (p = 0.007) in portacaval shunted rats in
relation to control rats. The serum concentrations of lipid
hydroperoxides (LOOH) and total thiols do not change in
PCS-rats (Figure 1).
Correlation between liver function parameters and serum 
redox status
The serum concentration of ammonia correlates with
albumin levels (r = 0.624; p = 0.04) and TAX correlates
with liver weight (r = 0.729; p = 0.017) and albumin levels
(r = 0.79; p = 0.007) (Figure 2).
Discussion
The results reported in this study show a significant
decrease of the TAX, associated with an increased AOPP
plasmatic level of portacaval-shunted rats. The considera-
ble decrease in TAX levels in long-term (4 weeks) porta-
caval shunted-rats suggest that a weakening of the
antioxidative barrier of the body exists, perhaps as a con-
sequence of the increased systemic oxidative stress pro-
duced by the portosystemic shunting in this experimental
model.
Oxidative stress, in general, is the overpowering of the
antioxidative defence system by the oxidative system [6].
A number of diseases, including liver disease [5], are asso-
ciated with an imbalance between oxidant stress and anti-
oxidative defence mechanisms that favour the former
[5,7]. Oxidative stress is produced by free radicals, i.e.,
reactive oxygen species (ROS) and reactive nitroxy species
(RNOS) and if they are not removed or neutralized, react
with lipids, proteins, and nucleic acids, damaging the cel-
lular functions and eventually causing cell death [5,6,8].
Both the excessive oxidative stress and the reduced anti-
oxidant ability could participate in the imbalance
between the oxidant stress and antioxidative defence
mechanism, which is produced in the rats with portacaval
shunt.
Chronic liver ischemia derived from the portal blood flow
bypass in the rat impairs oxidant scavenging, but does not
impair the oxidant generating systems of the liver [4].
However, the sources of ROS and RNOS in liver diseases
can be subdivided into intrahepatic and extrahepatic. Par-
ticularly, the extrahepatic oxidative stress is considered a
systemic phenomenon involving extrahepatic tissues [5]
and mainly portal circulation [5,9]. In rats with portal
Table 1: Body parameters. Initial body weight (IBW), final body weight (FBW), body weight increase (BWI), liver weight (LW) and 
liver weight/body weight ratio (LW/FBW) in control rats and in rats with portacaval shunt (PCS) at 4 weeks of evolution.
Group IBW (g) FBW (g) BWI (g) LW (g) LW/FBW × 100
Control (n = 11) 221.55 ± 5.01 267.82 ± 5,69 46.82 ± 6.35 7.48 ± 0,40 2.79 ± 0.14
PCS (n = 11) 237.64 ± 12.96 212.00 ± 22.19*** -25.09 ± 25.05*** 4.03 ± 0.63*** 1.90 ± 0.24***
Data presented as: Mean ± SD. ***Statistically different from the control group (p < 0.001).Page 2 of 8
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existence of a causal relationship between oxidative stress
and the hyperdynamic circulation developed has been
accepted [9]. Since the hepatocellular injury is not a fea-
ture of this animal model it has been proposed that oxida-
tive stress originates from the portal circulation and not
the diseased liver [5,9]. Furthermore, portacaval shunted
rats also develop a hyperdynamic splanchnic circulation
related to portosystemic shunting [10-12]. Therefore, in
this experimental model the hyperdynamic splanchnic
Table 2: Biochemical data. Aspartate-aminotransferase (AST), alanine-aminotransferase (ALT), AST/ALT ratio, ammonia, albumin, 
thiostatin and α 1 acid glycoprotein (α 1-AGP) serum concentrations in control rats and in rats with portacaval shunt (PCS), 4 weeks 
after the operation.
Group Control (n = 11) PCS (n = 11) p-value
AST (IU/L) 65.72 ± 11.19 134.50 ± 67.60 p = 0.004
ALT (IU/L) 29.36 ± 5.90 65.33 ± 27.27 p = 0.0001
AST/ALT 2.35 ± 0.08 2.38 ± 1.58 NS
Ammonia (μmol/L) 104.00 ± 48.05 274.00 ± 92.25 p = 0.0001
Albumin (g/dl) 2.89 ± 0.18 2.54 ± 0.08 p = 0.0001
Thiostatin (mg/ml) 0.09 ± 0.01 0.23 ± 0.04 p = 0.001
Data presented as: Mean ± SD. NS = non-significant difference.
Redox status in control rats and in rats with portacaval shunt at 4 weeks of evolutionFigure 1
Redox status in control rats and in rats with portacaval shunt at 4 weeks of evolution. Duplicate (TAX, AOPP and 
THIOLS) and triplicate (LOOH) assays in control (n = 11) and portocaval shunt (PCS) (n = 11) rats, except for TAX in which 
one PCS value was excluded. The results are expressed as mean ± SD. AOPP: serum advanced oxidation protein product; 
LOOH: serum lipid hydroperoxides; TAX: serum total antioxidant; THIOLS: total plasma thiols.Page 3 of 8
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ated with intestinal oxidative stress. It has been proposed
that the chronic hypoxemia of the intestinal mucosa
related to vascular congestion could be an etiologic key
factor in the production of bacterial translocation because
the enterocytes would suffer injury by oxidative stress
[13,14]. Moreover, NO-overproduction could represent
an adaptive mechanism of the endothelium in response
to chronic increases in flow-induced shear stress [15-18].
NO reacting with ROS, such as O2-., can also induce the
peroxynitrite ion (ONOO-) hyperproduction [19]. Intesti-
nal oxidative stress could participate through this mecha-
nism in the production of increased plasmatic levels of
AOPP in rats with a portosystemic shunt.
Protein oxidation products have increasingly been used as
markers instead of lipid peroxidation products in demon-
strating oxidative stress [20]. A novel oxidative stress
marker of protein, referred to as AOPP was developed in
plasma [21]. Furthermore, AOPP oxidation of plasma
thiol groups, termed "thiol stress," is quantitatively the
major manifestation of protein oxidation [22]. Since
AOPP is not only a marker of oxidative stress, but also acts
as an inflammatory mediator [23-27] the knowledge of
AOPP pathophysiology in this experimental model could
provide valuable information with respect to the relation-
ship between oxidative stress and the inflammatory
response related to a portosystemic shunt. In this regard,
since the liver and the spleen play important roles in the
elimination of AOPP [28], the apoptosis and liver atrophy
after portacaval shunting in the rat [29-31] could induce
its decreased plasma clearance, thus favouring its
increased plasmatic levels.
The marked plasmatic levels increase of thiostatin and the
hypoalbuminemia in rats with a portosystemic shunt may
be involved in the acute phase changes associated with a
systemic inflammatory response [32,33]. The proteins act-
ing as acute phase proteins differ from humans to animals
and from one species to another. In the rat, thiostatin and
α1-acid glycoprotein (α1-AGP) are among the major posi-
tive acute phase proteins while albumin reacts as a nega-
tive acute phase protein [34]. Thiostatin is a plasma
proteinase inhibitor protecting against proteolytic auto-
degradation [33]. Therefore, the synthesis of thiostatin
benefits from the metabolic priority during decreased
functional liver mass caused by the portosystemic shunt.
However, α1-AGP does not increase in these animals.
Since it is considered that α1-AGP prevents gram-negative
infections [34] and has anti-inflammatory functions [35],
rats with portacaval anastomoses would lose an essential
component in nonspecific resistance to infection and
inflammation.
Albumin plasma levels correlate with the TAX and with
the hyperammonemia in portosystemic shunted rats.
Albumin is a powerful extracellular antioxidant [36] and
its decreased liver synthesis after portacaval shunt reduces
Ammonia and total antioxidant statusFigure 2
Ammonia and total antioxidant status. Ammonia and 
serum total antioxidant (TAX) status are correlated with 
albumin serum levels. TAX also correlated with hepatic atro-
phy in portacaval shunted-rats 4 weeks after the operation.Page 4 of 8
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increases when ammonia levels are higher. This could rep-
resent an attempt of compensating the deleterious meta-
bolic effects caused by ammonium.
In rats with a portosystemic shunt, the acute-phase
response could be associated with oxidative stress, as well
as with inflammation. Particularly, IL-6, the major stimu-
lator of most acute phase proteins, is primarily produced
by Kupffer cells [37,38]. Upregulation of this cytokine
may be related to the enhanced respiratory burst activity
of Kupffer cells leading to the redox activation of NF-κB
[39-41]. This compensatory response has already been
described in order to re-establish homeostasis in the liver
and extrahepatic tissues exhibiting oxidative stress [38].
Another metabolic feature that has been shown to be
upregulated, though not always, due to a lack of oxygen or
oxidative stress, is the antioxidant system [42]. It has been
shown that the portosystemic bypass in the rat reduces the
oxidant scavenging system of the liver with a significant
reduction of superoxide dismutase and xanthine-dehy-
drogenase [4]. Furthermore, in the present study, the TAX
(i.e., the fraction of antioxidant pool available for further
anti-ROS activity) is significantly lower in portacaval
shunted rats compared to control rats. These results may
mean that a portosystemic shunt, including hyperdy-
namic circulatory syndrome and acute-phase response,
has its own effect on lowering TAX. Since oxidative stress
exhausts the antioxidative pool of the body, TAX could
also decrease [8,42]. However, the ROS overproduction
after portacaval shunting is not excessive, and indeed a
plasmatic increase of lipid peroxidation is not produced,
therefore it can be suspected that the novo antioxidant
synthesis is reduced. If so, the reduction of the systemic
antioxidant activity makes the organism susceptible to
oxidant-induce multi-organ injury because a normal ROS
production could be indeed a potential cause of oxidative
stress when an antioxidative deficit coexists [6,42-44].
Since the existence of an anti-inflammatory redox-oxidant
revolving axis has been suggested [43], in rats with porto-
systemic shunt, it could also be considered that the reduc-
tion of antioxidant ability would represent the mediator
signal for the evolution and perpetuation of the inflam-
matory process that is often associated with the condition
of oxidative stress, which involves gene regulation
[43,45]. Thus, the altered redox homeostasis in this exper-
imental model would be one of the hallmarks of the proc-
esses that regulate gene transcription in oxidative-stress-
mediated inflammation [8,43,45]. If so, we could call it:
"reduced antioxidative defence-mediated inflammation."
The decrease of the antioxidant protection in rats with
portacaval shunt, evidenced by lower TAX and hypoalbu-
minemia, is noteworthy since it is correlated with hyper-
ammonemia. This correlation suggests that, in this
experimental model, the grade of insufficient antioxidant-
mediated inflammation would be involved in a particular
metabolic alteration related to the portosystemic shunt, as
is the ammonia hyperproduction. Hyperammonemia is
considered a key etiopathogenic factor in the develop-
ment of hepatic encephalopathy [46-49]. Although,
ammonia is believed to be responsible for the neurologi-
cal abnormalities associated with hepatic encephalopa-
thy, growing evidence supports the view that glutamine,
synthesized from glutamic acid and ammonia, plays a
major role in the deleterious effects of ammonia [49] and
induce oxidative stress [46-48]. In turn, L-glutamic acid is
also a precursor of the antioxidant glutathione
[5,42,50,51]. Thus, hyperammonemia could be added as
an etiopathogenic factor of the oxidative stress-mediated
inflammation pathway that induces the portosystemic
shunt [48,49].
Conclusion
The decreased liver antioxidant activity in portacaval
shunted rats could potentiate the oxidative stress. In turn,
the increased synthesis of acute phase proteins by the
liver, since their anti-enzymatic ability, would attempt to
balance the enzymatic stress in this experimental model.
Methods
Animals
Male Wistar rats, with weights ranging from 230 to 270 g,
from the Vivarium of the Complutense University of
Madrid, were used. The animals were fed a standard labo-
ratory rodent diet (rat/mouse A04 maintenance diet, Pan-
lab, Spain) and water ad libitum. They were housed in a
light/dark-controlled room, with an average temperature
(22 ± 2°C) and humidity (65–70%) in groups of three to
four animals.
The experimental procedures and facilities complied with
the requirements of Commission Directive 86/609/EEC
(The Council Directive of the European Community) con-
cerning the protection of animals used for experimental
and other scientific purposes. The National legislation, in
agreement with this Directive, is defined in Royal Decree
n° 1202/2005.
Surgical technique of portacaval shunt
The animals were anesthetized by i.m. injection of keta-
mine (100 mg/Kg) and xylacine (12 mg/Kg). The end-to-
side portacaval anastomoses (PCA) was performed
according to a modified [29] Lee's technique [52,53]. In
brief, the intestinal loops are retracted to the animal's left
and covered with saline wet gauze to expose the inferior
vena cava (IVC) and the portal vein (PV). The dissection
and vascular anastomoses were done by a microsurgicalPage 5 of 8
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OPMI-1; 12 × 5). The IVC was dissected between the
hepatic parenchyma and the right renal vein. The PV was
individualized from the proper hepatic artery and the gas-
troduodenal vein was dissected and sectioned between
ligatures (silk 7/0). The infrahepatic IVC was clamped
with two microclips and an elliptical venotomy (3 × 2
mm) was performed on its anterior wall. The PV was then
ligated and sectioned in the liver hilum and clamped in its
confluence with the splenic vein. Nylon (9-10/0) was
used to perform the end-to-side portacaval anastomoses.
The midline abdominal incision was closed in two layers
using a continuous running technique with an absorbable
suture (polyglycolic acid) and 3-0 silk. Analgesia was
maintained with buprenorphine (0.05 mg/kg/8 h s.c.)
during the first 48 hours after the operation.
The animals were sacrificed by exsanguination 4 weeks
after the operation. Hepatic tissue was excised and rapidly
frozen in liquid nitrogen. Frozen livers were stored in
labelled containers at -80°C for posterior molecular stud-
ies and metabolic determinations.
Biochemical blood assays
Serum levels of albumin, total proteins, AST and ALT were
determined by routine laboratory methods using a
COBAS MIRA autoanalyzer according to the manufac-
turer's instructions (HORIBA ABX diagnostic, Montpel-
lier, France). Plasma ammonia was immediately
measured by glutamate dehydrogenase enzyme assay on a
clinical analyzer (COBAS MIRA autoanalyzer; Products:
BIOLABO SA, Maizy, France). Rat alpha-1-Acid Glycopro-
tein (alpha-1-AGP) and thiostatin serum levels were
assayed by ELISA (Life Diagnostics, Inc, USA)
Total antioxidant status
The total antioxidant capacity of serum was estimated in
duplicate using the commercial kit 'Total Antioxidant Sta-
tus' (Randox, UK), adapted to the Cobas Mira autoana-
lyser, which measures at 600 nm the formation of the
radical ABTS+ using the Reagent ABTS® in the presence of
H2O2 and peroxidase [54]. The method was calibrated
using the TROLOX standard included in the kit.
Determination of plasma sulfhydryl groups
Plasma sulfhydryl (-SH) groups were measured in dupli-
cate by using Ellman's reagent, 5,5'-dithiobis-(2-nitroben-
zoate) (DTNB), adapted to Cobas Mira [55]. Ten μl of
plasma were mixed with 200 μL of 0.1 M Tris buffer, con-
taining 10 mM EDTA, pH 8.2. The absorbance at 405 nm,
given by the plasma alone, was subtracted from that
obtained from the same sample 10 minutes after adding 8
μL of 10 mM DTNB. A blank containing only DTNB was
also included, and -SH concentration was calculated by
using a standard curve of glutathione. Thiol levels were
expressed in μmol/L plasma. Intra- and inter-assay varia-
tion coefficients were 1.2% and 6%, respectively.
Evaluation of plasma AOPP
Plasma AOPP were evaluated in duplicate by using a
microassay adapted to Cobas Mira according to Matteucci
et al [56] and based on the original method of Witko-Sar-
sat et al. [21]. Briefly, 10 μl of plasma or chloramine-T (ch-
T) standard solutions (400 – 6.25 μmol/l) were placed in
each well of the Cobas Mira autoanalyser. Then 200 μl of
the reaction mixture was added, consisting of 81% phos-
phate buffer solution (PBS), 15% acetic acid and 4% 1.16
mM potassium iodide. The absorbance was read at 340
nm (the blank contained PBS instead of plasma). AOPP
concentration was expressed as ch-T equivalents. Intra-
and inter-assay variation coefficients were 1% and 5%,
respectively.
Evaluation of plasma lipid hydroperoxides
Lipid hydroperoxides (LOOH) were evaluated in tripli-
cate by the FOX2 reagent (Ferrous Oxidation) automated
by Arab & Steghens [57] and adapted to Cobas Mira
(wavelength 600 nm) for studying lipid peroxidation in
serum samples. Xylenol orange (180 μl – 167 μM), the
first reagent, was added after to the sample (25 μl). The
first optical reading was recorded before adding 45 μl of
833 μM iron II D-gluconate. LOOH was calculated using
a standard curve of tert-butylhydroperoxide and LOOH
levels were expressed in μmol/L serum. Intra- and inter-
assay variation coefficients were 3% and 8%, respectively.
Statistical analysis
Statistical analyses were performed using SPSS software
(Statistical Package for the Social Sciences, version 14.00).
The results are expressed as mean ± standard deviation
(SD). Student's t test for independent data was used to
compare the different variables between the two groups of
animals. The relationship between the biochemical serum
parameters were verified using the Pearson coefficient cor-
relation. A p-value of less than 0.05 was considered signif-
icant.
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